AR015465A1 - Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento - Google Patents

Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento

Info

Publication number
AR015465A1
AR015465A1 ARP980105003A ARP980105003A AR015465A1 AR 015465 A1 AR015465 A1 AR 015465A1 AR P980105003 A ARP980105003 A AR P980105003A AR P980105003 A ARP980105003 A AR P980105003A AR 015465 A1 AR015465 A1 AR 015465A1
Authority
AR
Argentina
Prior art keywords
water
formulation
dibenz
azepin
carboxamide
Prior art date
Application number
ARP980105003A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR015465A1 publication Critical patent/AR015465A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una formulacion parental que comprende una 5H-dibenz(b,f)azepin-5-carboxamida y agua o un solvente basado en agua, donde la formulacion no contiene otrosauxiliares de solubilizacion. La formulacion parenteral es util en el tratamiento de ataques resultantes de por ejemplo, ataque epiléptico. Además se describeuna forma de dosificacion unitaria y un recipiente que comprende una cantidad terapéuticamente efectiva de 5H dibenz(b,f)azepin-5-carboxamida y el uso de dichaformulacion parenteral para lapreparacion de un medicamento
ARP980105003A 1997-10-09 1998-10-07 Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento AR015465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721497.7A GB9721497D0 (en) 1997-10-09 1997-10-09 Organic compounds

Publications (1)

Publication Number Publication Date
AR015465A1 true AR015465A1 (es) 2001-05-02

Family

ID=10820342

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105003A AR015465A1 (es) 1997-10-09 1998-10-07 Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento

Country Status (32)

Country Link
US (2) US6316417B1 (es)
EP (1) EP1033988B1 (es)
JP (2) JP2001519395A (es)
KR (1) KR100760326B1 (es)
CN (1) CN1210032C (es)
AR (1) AR015465A1 (es)
AT (1) ATE257383T1 (es)
AU (1) AU748034B2 (es)
BR (1) BR9812861A (es)
CA (1) CA2304661C (es)
CO (2) CO5090854A1 (es)
CZ (1) CZ298900B6 (es)
DE (1) DE69821024T2 (es)
DK (1) DK1033988T3 (es)
ES (1) ES2214738T3 (es)
GB (1) GB9721497D0 (es)
HK (1) HK1031824A1 (es)
HU (1) HU226106B1 (es)
ID (1) ID24134A (es)
IL (1) IL135123A0 (es)
MY (1) MY122129A (es)
NO (1) NO327263B1 (es)
NZ (1) NZ503526A (es)
PE (1) PE121998A1 (es)
PL (1) PL192287B1 (es)
PT (1) PT1033988E (es)
RU (1) RU2242231C2 (es)
SK (1) SK286253B6 (es)
TR (1) TR200000870T2 (es)
TW (1) TW584563B (es)
WO (1) WO1999018966A1 (es)
ZA (1) ZA989183B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20100204178A1 (en) * 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN101309691A (zh) * 2005-09-30 2008-11-19 奥瓦什医药品公司 新的胃肠外的卡马西平制剂
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN101711739B (zh) * 2008-10-08 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 卡马西平的口服药物组合物
CN105726466A (zh) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 一种奥卡西平注射剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010072D1 (de) * 1989-12-27 1996-02-29 Ciba Geigy Ag Vorrichtung zum Homogenisieren der inhomogenen Lichtverteilung eines Laserstrahllichtbündels
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Also Published As

Publication number Publication date
NO327263B1 (no) 2009-05-25
CA2304661C (en) 2007-12-11
KR100760326B1 (ko) 2007-09-20
PT1033988E (pt) 2004-05-31
RU2242231C2 (ru) 2004-12-20
HU226106B1 (en) 2008-04-28
WO1999018966A1 (en) 1999-04-22
JP2001519395A (ja) 2001-10-23
KR20010072533A (ko) 2001-07-31
HUP0004362A2 (hu) 2001-08-28
BR9812861A (pt) 2000-08-08
ES2214738T3 (es) 2004-09-16
SK286253B6 (sk) 2008-06-06
ATE257383T1 (de) 2004-01-15
MY122129A (en) 2006-03-31
ID24134A (id) 2000-07-06
US6316417B1 (en) 2001-11-13
GB9721497D0 (en) 1997-12-10
HK1031824A1 (en) 2001-06-29
DE69821024T2 (de) 2004-10-28
NO20001730D0 (no) 2000-04-04
EP1033988A1 (en) 2000-09-13
CN1210032C (zh) 2005-07-13
DK1033988T3 (da) 2004-04-13
CZ20001279A3 (cs) 2000-07-12
ZA989183B (en) 1999-04-09
EP1033988B1 (en) 2004-01-07
AU748034B2 (en) 2002-05-30
NO20001730L (no) 2000-04-04
PL339446A1 (en) 2000-12-18
DE69821024D1 (de) 2004-02-12
CZ298900B6 (cs) 2008-03-05
SK5052000A3 (en) 2000-12-11
NZ503526A (en) 2003-01-31
PL192287B1 (pl) 2006-09-29
CO5090854A1 (es) 2001-10-30
CN1274286A (zh) 2000-11-22
CA2304661A1 (en) 1999-04-22
TR200000870T2 (tr) 2000-10-23
PE121998A1 (es) 1999-12-08
US20020055503A1 (en) 2002-05-09
AU9629898A (en) 1999-05-03
TW584563B (en) 2004-04-21
HUP0004362A3 (en) 2006-06-28
JP2005281314A (ja) 2005-10-13
CO4950520A1 (es) 2000-09-01
IL135123A0 (en) 2001-05-20
US6458770B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
ES2062632T3 (es) Composicion para tratamiento del cabello.
DE69212729D1 (de) Arzneibehälter und Verabreichungssystem
NO953769L (no) Pakninger for brettede servietter til engangsbruk og som bevirker utbretting
AR019818A1 (es) Un inmunoconjugado de miostatina.
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
ES2114931T3 (es) Nuevos esteres esteroidales.
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
ATE221059T1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
AR018026A1 (es) Un material tramado al azar con suavidad mejorada y propiedades de barrera y peso base reducido
AR015465A1 (es) Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento
CO5170409A1 (es) Composiciones antitranspirantes
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
ES2097461T5 (es) Agente impeditivo de incrustaciones de polimeros.
DK0560900T3 (da) Forebyggelse af synovialadhæsioner
ES2176702T3 (es) Antimicoticos con alta liberacion de sustancia activa.
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
ID21282A (id) Senyawa-senyawa cincin beranggota-5 terpadu yang disubstitusi sulfonamida, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung senyawa tersebut
ID19931A (id) Senyawa cincin 7-anggota terfusi tersubstitusi sulfonamida, penggunaannya sebagai obat-obatan, dan pembuatan sediaan farmasi yang mengandung senyawa tersebut
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
ATE263547T1 (de) Pharmazeutische mischung, die ein profen und weitere aktivsubstanzen enthält
ES2127305T3 (es) Una forma farmaceutica para la administracion rectal de compuestos farmacologicamente activos.
KR880012231A (ko) 스테로이드의 용도
ITMI931622A0 (it) Procedimento e apparecchiatura di trattamento del liquido di bagnatura in macchine da stampa, particolarmente per macchine da stampa offset.
ES2134502T3 (es) Recipiente desechable para liquidos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure